Accupril

Selected form

Quinapril Hydrochloride

Method of action: Agents Acting In The Renin-Angiotensin System, Antihypertensive, Hypotensive

Treatment option: Agranulocytosis, Angioedema, Hyperlipidemia, Hypertension, Diabetic Kidney Disease, Cerebrovascular Accident, Collagen Vascular Disease, Smoking, Smoking Cessation, Diabetes Mellitus

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Accupril

What is Accupril?

Accupril is a prescription medication primarily used in the management of high blood pressure (hypertension) and as an adjunctive treatment for heart failure. It belongs to a class of drugs known as angiotensin-converting enzyme (ACE) inhibitors.

Mechanism of Action

The active ingredient in Accupril is quinapril hydrochloride. It works by blocking the action of a specific enzyme in the body that produces angiotensin II, a substance that causes blood vessels to tighten and narrow. By inhibiting this enzyme, the medication allows blood vessels to relax and widen, which helps to lower blood pressure and improves the efficiency of the heart's pumping action.

Therapeutic Use

Hypertension: By lowering elevated blood pressure, the medication helps reduce the long-term workload on the heart and arteries.
Heart Failure: In patients with heart failure, it is often used alongside other treatments to help manage symptoms and improve cardiac function by reducing the resistance against which the heart must pump.

Composition

Accupril is formulated as an oral tablet. In addition to the active ingredient quinapril, the tablets contain inactive components used for stabilization and pill formation, such as magnesium carbonate, gelatin, lactose, and magnesium stearate.

Regulatory References

National Institutes of Health, MedlinePlus

What side effects are possible with Accupril?

Possible Side Effects and Safety Information

This information details the officially documented adverse effects and safety characteristics of Accupril (quinapril hydrochloride), based strictly on government regulatory documents such as the FDA Prescribing Information and the European Summary of Product Characteristics (SmPC).

Serious Adverse Reactions and Warnings

Regulatory documents emphasize specific, potentially life-threatening risks. Angioedema (severe swelling of the face, extremities, lips, tongue, or larynx) is a documented serious adverse reaction, potentially resulting in fatal airway obstruction. The medicine carries a regulatory Boxed Warning for Fetal Toxicity; use during the second and third trimesters of pregnancy is contraindicated as it can cause injury and death to the developing fetus.

Common and Less Frequent Adverse Reactions

Adverse reactions are classified by frequency as observed in clinical trials:

Common (Reported in ge 1% of patients): Headache, dizziness, fatigue, persistent dry coughing, nausea/vomiting, abdominal pain, and diarrhea. Increases in serum creatinine and blood urea nitrogen (BUN) are also noted as common findings.
Uncommon: Hypotension, chest pain, palpitations, insomnia, nervousness, syncope, and rash.

Population-Specific Safety Constraints

Official labeling includes safety considerations for certain patient groups:

Pregnancy: The medication is contraindicated in the second and third trimesters. Immediate discontinuation is required upon detection of pregnancy.
Black Patients: Studies have shown a higher reported incidence of angioedema when ACE inhibitors are used as monotherapy.
Renal Impairment: Close monitoring of renal function and serum potassium levels is required due to the potential for acute renal failure, especially in patients with pre-existing conditions.

Safety Limitations and Patterns

Symptomatic hypotension is noted in regulatory documents as being more likely to occur specifically at the initiation of therapy or in patients who are volume-depleted. The medication is contraindicated in individuals with a history of angioedema related to previous ACE inhibitor treatment or hereditary angioedema.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory guidance for Accupril (quinapril) mandates that patients seek immediate medical attention and contact a Poison Control Center immediately if an overdose is suspected. This required emergency action is due to the primary serious risk documented in the regulatory labeling.

The most likely clinical manifestation of an overdose is the development of symptoms attributable to severe hypotension (a profound drop in blood pressure). This classification highlights the drug’s potential impact on the circulatory system when taken in excess.

Management is focused on symptomatic and supportive treatment, as no specific antidote is widely available. To manage severe hypotension, procedures described in the official profile include placing the patient in the supine position and administering an intravenous infusion of normal saline for volume expansion.

Regulatory documents further clarify that standard laboratory determinations of drug or metabolite levels have no established role in management, and hemodialysis or peritoneal dialysis have little effect on eliminating the drug from the body.

Therapeutic Uses of Accupril

Accupril (quinapril) is commonly used across therapeutic domains where long-term cardiovascular support is needed. Its core therapeutic focus is commonly used to help with managing essential hypertension (high blood pressure) and providing supportive relief for chronic heart failure.

The medication is relevant in scenarios where symptoms that interfere with daily functioning are present. This involves addressing symptoms related to heightened physiological activity (high blood pressure) and managing symptom clusters associated with chronic heart failure, such as fatigue, dyspnea (shortness of breath), and fluid retention. This therapeutic approach provides support that helps ease the overall symptom burden and contributes to improved comfort during periods of heightened symptoms.

Accupril may be part of symptomatic management in patient groups, including those with diabetes, where it is relevant for conditions presenting with systemic discomfort.

Quick Fact: Symptom Support
The supportive use in heart failure assists with maintaining functional stability and easing symptoms like fluid retention (edema).

Regulatory References

DailyMed by the National Library of Medicine

Eligibility and Restrictions for Use

Accupril (quinapril) is approved for use in adult patients for its established indications. Eligibility rules are defined by official regulatory bodies, primarily through absolute prohibitions and conditions that necessitate careful management.

Contraindicated (Must Not Use)

Contraindication	Basis
Pregnancy	Absolute prohibition due to high risk of severe fetal injury or death.
Angioedema History	Contraindicated if there is a history of angioedema related to a previous ACE inhibitor.
Dual RAS Blockade	Contraindicated with Neprilysin Inhibitors (e.g., sacubitril/valsartan) and with Aliskiren in patients with diabetes or moderate-to-severe renal impairment.

Restricted and Conditional Use

Population Constraint	Restriction/Limitation
Pediatric Patients	Use is not recommended; safety and effectiveness have not been established.
Renal Impairment	Requires a reduced starting dose and cautious monitoring based on creatinine clearance (CrCl).

Patients with subaortic stenosis are also explicitly contraindicated according to certain official labels. While the drug is present in breast milk, use during lactation is generally advised with caution.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Accupril (Quinapril) includes specific combination constraints and documented kinetic and dynamic patterns based on regulatory labeling.

Contraindicated Combinations

Sacubitril/Valsartan: Co-administration is prohibited due to a significantly increased risk of angioedema. A mandatory 36-hour separation window is required when switching to or from this agent.
Aliskiren: The combination is contraindicated in patients with diabetes mellitus due to elevated risks of hypotension, hyperkalemia, and renal dysfunction.
Procedural Restrictions: The medicine is contraindicated for use during hemodialysis with high-flux polyacrylonitrile (PAN) membranes.

Documented Pharmacodynamic Effects

Co-administration with other agents may result in additive effects, as documented by official sources:

Potassium-Elevating Agents: Combining with potassium-sparing diuretics or potassium supplements may result in hyperkalemia.
NSAIDs: Non-Steroidal Anti-Inflammatory Drugs may attenuate the antihypertensive effect of Accupril and increase the risk of renal function deterioration.
mTOR Inhibitors: The combination with drugs like Sirolimus is associated with an increased risk for angioedema.

Exposure-Modifying Interactions

Lithium: Co-administration reduces the renal clearance of Lithium, leading to increased serum levels and potential toxicity.
Food/Antacids: A high-fat meal or antacids containing magnesium/aluminum reduce the rate and extent of quinapril absorption.

Mechanism of Action

Accupril (quinapril) is an inactive ethyl ester prodrug that is rapidly de-esterified primarily by hepatic carboxylesterases to its active metabolite, quinaprilat.

Quinaprilat acts as a competitive inhibitor of the angiotensin-converting enzyme (ACE), a peptidyl dipeptidase located on the surface of vascular endothelial cells throughout the systemic circulation and tissue beds. By blocking the active site of ACE, quinaprilat prevents the conversion of the decapeptide angiotensin I (Ang I) into the octapeptide angiotensin II (Ang II).

The reduction of Ang II concentration systemically and locally leads to multiple downstream cascades: a decrease in direct vasoconstriction mediated by Ang II receptors, a reduction in Ang II-stimulated aldosterone secretion from the adrenal cortex, and a consequent modulation of renal sodium and water reabsorption.

Furthermore, ACE is kinetically identical to kininase II, the enzyme responsible for degrading the vasodilator peptide bradykinin. Inhibition of ACE leads to an increased concentration of bradykinin, which promotes nitric oxide release and contributes to vasodilation. The system-level physiological consequence of these combined molecular interactions is a reduction in total peripheral vascular resistance and a decrease in effective circulating volume.

Dosage and Administration Information

Instruction Map: How to use Accupril — Administration Guidelines

This map summarizes the usage instructions for Accupril (Quinapril) tablets.

Administration Scope

Instruction	Detail
Route of Administration	The medicine is administered via the oral route as film-coated tablets.
Dosing Schedule	Therapy begins with a low initial dose that is then adjusted (titrated) over time. For hypertension, the starting dose is 10 mg or 20 mg once daily; for heart failure, the initial dose is 5 mg twice daily. Maximum doses are typically 80 mg daily for hypertension and 40 mg daily for heart failure.
Timing in Relation to Meals	May be administered without regard to meals; however, a high-fat meal may moderately diminish the rate and extent of absorption.
Age-Group Administration Rules	Patients 65 years are generally started at 10 mg once daily, followed by a gradual titration.
Special Procedural Conditions	The initial dose must be adjusted based on renal function (Creatinine Clearance). Diuretics should, if clinically possible, be discontinued 2–3 days prior to initiation. Close medical supervision for 2 hours is required following the first dose for heart failure.

Instruction Classifications (High-Level)

Classification	Detail
Administration method type	Oral (tablet).
Frequency pattern	Daily (once or twice daily, depending on indication).
Use-context constraints	Mandatory dose adjustment for renal impairment; procedural management of diuretic use.

Resulting Procedural Structure

Step Sequence:

Determine the initial dose based on the indication and required adjustment for renal function or age.
Discontinue diuretics 2-3 days before starting quinapril, if medically appropriate, or initiate at the reduced 5 mg dose under supervision.
Administer the dose orally and monitor closely for a period of at least two hours after the first dose for heart failure.
Titrate the dosage at defined intervals, such as weekly (heart failure) or every two weeks (hypertension), toward the long-term maintenance dose.

Connection to the Overall Use Protocol

The protocol for using Accupril centers on a chronic, long-term administration pattern. This pattern is defined by a structured initial dose titration process over weeks, which accounts for the patient's existing renal status and concurrent diuretic use before reaching the final maintenance regimen.

Recent Clinical Evidence

Clinical evidence for quinapril (Accupril) primarily focuses on its established use as an Angiotensin-Converting Enzyme (ACE) inhibitor for the management of hypertension (high blood pressure) and as adjunctive therapy in patients with heart failure.

Studies in Hypertension

Research has consistently evaluated quinapril's role in achieving and maintaining target blood pressure levels. Multiple randomized, controlled trials (RCTs) demonstrated that quinapril, used either as monotherapy or in combination with other anti-hypertensive agents, was associated with statistically significant reductions in both systolic and diastolic blood pressure compared to placebo. Studies have also explored its efficacy across diverse patient populations, including the elderly and those with co-existing conditions like diabetes. The therapeutic effect is generally observed within one to two hours of administration, with peak effect occurring within two to six hours.

Evidence in Heart Failure

For patients with heart failure, clinical data supports the use of quinapril to manage symptoms and improve overall clinical status. Studies indicate that the inclusion of quinapril in a patient's regimen can support ventricular function and improve exercise tolerance. Its mechanism of inhibiting ACE reduces peripheral resistance and blood volume, lessening the workload on the heart, which is a key therapeutic goal in managing chronic heart failure.

Safety and Tolerability Profile

Quinapril's safety profile is well-documented from extensive clinical use. Common side effects reported in trials include headache, dizziness, fatigue, and cough. The risk of angioedema (a serious form of swelling) is a known consideration for all ACE inhibitors, and this risk is highlighted in the labeling based on clinical trial data.

How should Accupril be stored and disposed of?

Accupril tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from light and moisture to maintain stability. Tablets should be kept in the original container, which must be a well-closed container sealed tightly closed. The medication must always be stored out of the sight and reach of children, utilizing locked safety caps. Do not store the product in areas with excess heat or moisture, such as a bathroom. To dispose of unused or expired tablets, do not flush them down a toilet or pour them into a drain. Disposal should follow the guidance of a pharmacist regarding local collection or drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.